IL-6 inhibitors currently exhibits a growing
pipeline with approximately 18 active drug candidates, P&S Market Research
The study analyzed that the IL-6
inhibitors therapeutics pipeline
comprises approximately 18 active drug candidates in different stages of
development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors
belong to a group of cytokine receptors that are expressed by leukocytes and
plays an important role in the functioning of the immune system. It has a
characteristic role in systemic inflammation in numerous disease conditions,
including rheumatoid arthritis, and psoriatic arthritis.
According to the research findings, most of the
drug candidates of the IL-16 inhibitors are being developed as the monoclonal
antibody.
The positive clinical results from IL-6 inhibitors
drug candidates have been driving the pipeline growth. GlaxoSmithKline plc
presented results from two pivotal Phase III studies (NCT01606761; NCT02019472)
evaluating subcutaneous sirukumab. In both the studies, sirukumab met the
primary endpoint showing significant improvement in the signs and symptoms of
moderately to severely active rheumatoid arthritis compared to placebo.
Download Report Sample Copy at: https://www.psmarketresearch.com/market-analysis/interleukin-6-inhibitors-therapeutics-pipeline/report-sample
In January 2017, Tiziana Life Sciences plc acquired
an exclusive world-wide license for NI-1201, a fully human anti-IL-6R
monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive
license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash
payment, milestone payments, and a royalty on future sales.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=interleukin-6-inhibitors-therapeutics-pipeline
Some of the key players developing drugs for the
treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai
Pharmaceutical Co., Ltd., Vitaeris Inc. and others.
IL-6 Inhibitors Therapeutics Pipeline
Analysis
·
By Phase
·
By Molecule Type
·
By Route of
Administration
·
By Company
